PolyNovo trade agreed

By Dylan Bushell-Embling
Thursday, 02 October, 2008

Xceed Capital [ASX: XCD] has agreed to sell its 64 per cent stake in PolyNovo Biomaterials to Metabolic Pharmaceuticals [ASX: MBP].

The sale has been on the cards for some time, but both parties have finally signed off on the deal.

Under the arrangement Xceed, an investment company, will trade Metabolic its stake in return for 1.5 MBP shares for every PolyNovo share Xceed owns.

The deal must still be approved by both Xceed and Metabolic shareholders. Xceed is holding a shareholder's meeting to discuss the sale in November.

Related News

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...

Newborns have elevated levels of an Alzheimer's biomarker

What do the brains of newborns and patients with Alzheimer's disease have in common? Both...

Cannabis use may double risk of cardiovascular disease death

Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd